Bronchiolitis Obliterans Syndrome
QNCXQuince TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor) in Bronchiolitis Obliterans Syndrome. The expected timing is based on the latest available company guidance and may change.
05/18/26:- Ongoing Phase 2 in BOS; data expected Q1 2027. 08/14/26:- Phase 2 BOS trial is fully enrolled. Data is expected in Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.